+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID05357846

Phase 3 Study Comparing PD-1 Inhibitor Plus Chemoradiotherapy and Surgery Versus Chemoradiotherapy and Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma

Led by Sun Yat-sen University · Updated on 2026-04-30

422

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are comparing a PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery to neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced squamous cell esophageal carcinoma ESCC. The study focuses on patients with Stage T1-4aN1-3M0 or T3-4aN0M0 ESCC, aiming to evaluate overall survival time. This Phase III randomized controlled trial is led by Sun Yat-sen University and targets patients aged 18 to 70 years with potentially resectable tumors who have not received prior anticancer therapy. Participants are divided into two groups. The experimental group NCRTIO receives a PD-1 inhibitor called sintilimab by intravenous infusion on days 1 and 22, along with concurrent chemoradiotherapy, which includes radiation 40 or 45 Gy over 4 weeks and chemotherapy drugs paclitaxel and cisplatin given intravenously on days 1, 8, 15, and 22. The comparator group NCRT receives the same chemoradiotherapy without the PD-1 inhibitor. Surgery, consisting of esophagectomy with lymph node dissection, occurs 6 to 8 weeks after chemoradiotherapy. During the study, participants undergo detailed monitoring including evaluation of overall survival over up to 5 years of follow-up. Secondary outcomes include progression-free survival, pathologic complete response rate, R0 resection rate, perioperative complications, and mortality assessed up to 90 days after surgery. Patients are assessed for blood counts, organ function, and general health status before and during treatment. The study ensures careful follow-up to measure treatment effects and safety outcomes over an extended period.

CONDITIONS

Brief Title

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Research Team

H

HONG YANG, M.D. Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here